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The purpose of this paper is to understand the association between antiepileptic drugs (AEDs), patient characteristics, changes in
seizure pattern and emergent psychiatric disorder, i.e. psychosis or affective disorder. To this end we carried out a retrospective
casenote study on 89 patients who developed psychiatric symptoms during treatment with topiramate, vigabatrin or tiagabine.
The psychiatric problem was either an affective or a psychotic disorder (not including affective psychoses). It was discovered
that 99% of the patients suffered from complex partial seizures with or without secondary generalization. More than half
were on polytherapy with two or more other AEDs. Nearly two-thirds had a previous psychiatric history. There was a strong
association between the type of previous psychiatric illness and the type of emerging psychiatric problem, both for psychoses
and for affective disorders. Patients on vigabatrin had an earlier onset of epilepsy and more neurological abnormalities than
those on topiramate. Those patients on lower doses had a shorter interval between the start of the AED therapy and the onset
of the psychiatric problem. A seizure-free period was observed in more than half of the patients before they developed the
psychiatric symptoms, and of these more were likely to develop a psychosis rather than an affective disorder. There seemed to
be an association of suppression of right-sided seizures and the onset of the psychiatric problem. The conclusions drawn were
that patients with a previous history of psychosis or affective disorder tended to develop the same psychiatric problem with new
AEDs. Those with a seizure-free period before the onset of the psychiatric problem were more likely to develop a psychosis
than an affective disorder.
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INTRODUCTION
It is well known that antiepileptic drugs can lead to
alterations of behaviour and mood. In the past barbi-
turates, and in particular polytherapy, have been asso-
ciated with irritability and depression, which stand in
contrast to the potential beneficial effects of some of
these drugs. For example, carbamazepine and sodium
valproate now have an established place in the man-
agement of bipolar affective disorders in psychiatric
practice1. In contrast to affective disorders and irri-
tability, psychoses have also been reported. Perhaps
the most interesting reports originally came from the
work of Landolt2 when he observed the phenomenon
of forced normalization in patients who were given the
then newly prescribed ethosuximide. In these cases,
suppression of seizures with ethosuximide led to a
normalization of the previously abnormal EEG pat-
terns, and a flowering of a psychosis. Tellenbach3 gave
the name ‘alternative psychosis’ to the clinical pattern
without the underlying EEG evidence of normaliza-
tion.
Psychoses have been observed with a number of
other antiepileptics, but have recently been reported
more frequently following the introduction of several
new antiepileptic drugs in the last decade.
At the National Hospitals we have seen both affec-
tive disorders and psychoses as treatment-emergent ef-
fects of several of the newer agents, and have pub-
lished data on some of these4. In this paper we exam-
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ine an extensive series of patients who presented with
treatment-emergent psychiatric effects following the
prescription of one of three new antiepileptic drugs,
namely, vigabatrin, topiramate or tiagabine. We exam-
ine certain hypotheses, but particularly look at the ef-
fects on the mental state of the alteration of seizure
pattern with the drugs.
MATERIALS AND METHODS
Patients in this study have been collected from sev-
eral sources. Data on some patients have been previ-
ously published in a retrospective survey on vigaba-
trin. Most of those patients were seen and examined
at the National Hospitals for Neurology and Neuro-
surgery, or the Chalfont Centre for Epilepsy, and they
comprise the ‘vigabatrin group’. There are five pa-
tients who were prescribed tiagabine and who went on
to develop treatment emergent psychopathology, these
all came from the Chalfont Centre for Epilepsy. These
are referred to as the ‘tiagabine group’. Finally, there
are patients who have been reported as having devel-
oped similar effects following topiramate. These come
from three centres (London, Birmingham and York)
and are referred to as the ‘topiramate group’.
Data were collected on 94 patients who developed
a psychiatric problem while being treated with one of
the new antiepileptic drugs. Thus, the patients’ notes
were reviewed and detailed clinical information ob-
tained. Where insufficient information was available
the cases were no longer considered. Five patients
were excluded for the following reasons: two because
of a final diagnosis of pseudoseizures; one suffered
from PTSD; one patient was intoxicated with pheny-
toin; and finally one case was complicated because
several other drugs were being stopped and started si-
multaneously. So 89 patients were finally included in
the study.
Following a review of the notes, patients were allo-
cated into two main groups based upon the descriptive
psychopathology. These were affective disorders and
psychoses. Affective disorder ranged from severe dys-
thymia to affective psychosis, the latter always hav-
ing mood-congruent delusions. A majority, however,
had a major affective disorder. The designation ‘affec-
tive disorder’ was given only to patients who required
psychiatric intervention or psychiatric assessment for
their disorder.
The psychoses included patients with organic
deliria, and inclusion criteria required delusions and/or
hallucinations. The delusions would not be mood con-
gruent. The psychoses could occur in clear conscious-
ness, in which case they would be referred to as
schizophrenia-like or paranoid, or with confusion, in
which case they would be organic and deliria. The
latter often, but not always, included post-ictal psy-
choses.
Following the collection of data the patient informa-
tion was analysed on SPSS, version 7.5. Chi-square
statistics were used for binomial data, or Fisher’s ex-
act test when the expected frequency in at least one
cell was less than five. For comparison of means we
performed t-tests, or Mann–Whitney tests if the data
were not normally distributed.
RESULTS
Of the 89 patients, vigabatrin was prescribed to
50 (56%), topiramate to 34 (38%) and tiagabine to
5 (6%) (Table 1).
With respect to diagnosis, 40 patients (45%) suf-
fered from an affective disorder, 30 (34%) with de-
pression but also 8 (9%) with affective psychosis
or hypomania (2). In 49 cases (55%) there was a
psychosis (excluding affective psychoses). The psy-
choses were (one case was unclear) 11 (12%) organic
deliria, including the post-ictal states and 37 (42%)
schizophrenia-like or paranoid states.
Of the patients, 54 (61%) were female, and the
mean age was 34.7 years, with a range from 14 to 67
(SD 12.3). There were 28 (70%) women among the
affective group and 26 (53%) in the psychosis group
(chi-square = 2.6; P = 0.10).
The mean age of onset of the epilepsy (unknown
in two cases) was 11.8 years (SD 12.2); however, it
was significantly lower in the vigabatrin group than
in the topiramate group (8 and 17 years respectively;
t-test for independent samples: t = −3.5; two-tailed
significance < 0.01; 95% CI −14.9 to −3.1). Symp-
tomatic epilepsy (53, 61%) was more common than
cryptogenic (34, 39%) (two unclear cases). There were
less cryptogenic cases in the topiramate group (4 of
32, 13%) than in the vigabatrin group (28 of 50, 56%)
(chi-square = 15.5, P < 0.001).
The most common seizure type (unknown in one)
was complex partial seizures (70, 80%), followed by
secondarily generalized seizures (37, 42%); 79 pa-
tients (90%) had complex partial seizures with or
without secondary generalization. Primary general-
ized seizures were observed in 18 cases (20%), 10
(11%) of whom had both generalized and partial
seizures and eight (9%) generalized seizures only.
Twenty-eight psychotic patients (57%), but only nine
affective patients (23%) suffered from secondarily
generalized seizures (chi-square = 10.3; P < 0.01).
A neurological examination (done in 84 patients)
was abnormal only in 12 (14%). There were signifi-
cantly more abnormalities in the vigabatrin group (11,
22%) than in the topiramate group (1, 3%) (chi-square
= 6.0; P < 0.05).
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Table 1: Basic clinical information
Vigabatrin Topiramate Tiagabine
N = 50 N = 34 N = 5
Mean age (SD) 33.0 (12.6) 37.2 (11.9) 35.4 (12.6)
Sex (% females) 62% 62% 40%
Mean age of onset of 8.4 (8.0) 17.4 (15.5) 7.8 (11.5)
epilepsy (SD)
Number of psychoses 28 18 3
Number of affective 22 16 2
disorders
Past psychiatric history of 9 6 2
psychosis
Past psychiatric history of 13 16 1
affective disorder
Mean dose per day (SD) 2.7 g (1.4) 293 mg (182) 29.6 mg (22.2)
33.3
0
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Fig. 1: Topiramate dose in mg/day. Mean 292.6, SD 182.3,
N = 34.
Seventy-three patients had CT or MRI imaging car-
ried out, and 36 (49%) had abnormal findings. In
28 cases (38%) there was a lateralized lesion, with
17 (23%) lesions in the right hemisphere being non-
significantly more common than 11 (15%) in the left.
Depressive patients had a higher proportion (18, 64%)
of CT/MRI abnormalities than psychotic patients (18,
40%) (chi-square = 4.1; P < 0.05). Of 15 patients
with a right-sided abnormality all showed either a pe-
riod of seizure suppression or a decrease in seizure
frequency prior to the onset of psychiatric problems
(10 affective disorders and five psychoses), but only
six (55%) of those with an abnormality in the left side
(chi-square = 8.4; P < 0.01).
Eighty patients had an EEG which revealed abnor-
malities in 77 (96%), which were bilateral in 35 (44%),
left sided in 20 and right sided in 22. Bilateral EEG
abnormalities were nonsignificantly more common in
the psychosis group (24, 52%) than in the depression
group (11, 32%) (chi-square = 3.1; P = 0.08).
Only one patient was on monotherapy with the new
drug. Aside from the new drug 40 (45%) were on
monotherapy with another antiepileptic, mostly with
carbamazepine (30, 34%), and 48 (55%) were on poly-
therapy with two or more other drugs. All in all car-
bamazepine was given to 62 patients (70%), pheny-
toin to 22 (25%) and sodium valproate to 13 (15%).
Nine patients also took clobazam, eight lamotrig-
ine, seven gabapentin and six each received clon-
azepam or primidone. Four were on phenobarbitone,
four on vigabatrin (in addition to topiramate (three) or
tiagabine (one) as the index drug), one on tiagabine (in
the topiramate group) and one on diamox.
Vigabatrin was given at a mean dose of 2.7 g/day
(SD 1.4), tiagabine with a mean of 29.6 mg/day
(SD 22.2) and topiramate with 293 mg/day (SD 182).
The distribution of doses with the latter drug sug-
gested a bimodal distribution, with patients on either
400 mg/day or more (13, 38%) or on 300 mg or less
(21, 62%) (see Fig. 1). There was no similar bimodal
distribution on tiagabine or vigabatrin.
Arbitrarily taking more than 3 g of vigabatrin, over
40 mg of tiagabine and over 300 mg of topiramate as
‘high doses’, of 89 patients (the dose being unknown
in one case) we distinguished 66 patients on a ‘low
dose’ from 22 patients (25%) on a ‘high dose’. There
were eight (16%) patients on over 3 g vigabatrin, one
patient (20%) on over 40 mg tiagabine and 13 (38%)
patients on over 300 mg topiramate per day.
We suspect from clinical experience that the onset
of the psychiatric problem is often associated with an
increase in dose of an antiepileptic. However, due to a
lack of information this could only be confirmed in 11
(12%) of our cases.
The time interval (unknown in two cases) between
the prescription of one of the new antiepileptics and
the onset of psychiatric symptoms was very vari-
able, from immediate onset after the first dose to over
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4 years, with a median of 8 weeks. The group of pa-
tients on a high dose (see above) had a much longer
interval (median of 25 weeks) than the low dose group
(median of 7 weeks), Mann–Whitney U = 349.5 and
P < 0.001.
In 32 patients (36%), no evidence for any psychi-
atric history was found. Thirty (34%) had previously
suffered from anxiety or depression, 17 (19%) from a
psychotic episode and 10 (11%) from other disorders,
e.g. behavioural problems or personality disorders.
There was a strong association between the psychi-
atric history and the present psychiatric problem: 15
of all psychotic patients (31%) but only two affective
patients (5%) had a history of psychosis (chi-square=
9.3, P < 0.01). Similarly 20 of all affective patients
(50%), but only 10 psychotic patients (20%) had had
an affective disorder (chi-square = 8.6, P < 0.01).
Just before the onset of the psychiatric symptoms,
five different patterns of seizures occurred (unknown
in six): in 22 patients (27%) the seizures were com-
pletely suppressed, 20 patients (24%) had a seizure-
free interval followed by a cluster of seizures (post-
ictal); there was a decreased frequency, but not free-
dom from attacks in 22 (27%), no change in 16 (19%)
and more seizures in three (4%) patients.
With regards to completely seizure-free patients,
there was a higher proportion in the psychosis group
(15, 34%) than in the depression group (7, 18%) (not
significant, chi-square = 2.8; P = 0.10). There was
a difference, however, between the group on vigaba-
trin and those on topiramate (Table 2). The group on
topiramate had more affective patients with complete
resolution of seizures. There were more patients with
no change in seizure frequency or even more seizures
in the topiramate group (10, 33%) than in the vigaba-
trin group (7, 16%); however, this was not significant
(chi-square = 2.4; P = 0.12).
There was, however, a significant relationship with
psychiatric diagnosis. Following the two seizure pat-
terns with a seizure-free period, i.e. complete suppres-
sion of seizures or suppression of seizures followed by
clusters, there were significantly more psychoses (27,
61%) than depressions (15, 38%) (chi-square = 4.3;
P < 0.05). Again there were differences between top-
iramate and vigabatrin, the latter showing more psy-
chosis than depression.
We then analysed the difference between patients
who became seizure-free or had a reduced frequency
of attacks, but no differences emerged (Table 3).
DISCUSSION
In this paper we have analysed the data from patients
who have developed either an affective disorder or a
psychosis as a treatment emergent effect of one of
three new antiepileptic agents. There are always prob-
lems with retrospective data, not the least being the
amount of missing data. Further, clinical descriptions
of, for example, the phenomenology of the mental
state, are often less than adequate. We have been for-
tunate to have almost complete data on most of the
variables we have been examining, and generally the
quality of the clinical material available to us was sat-
isfactory. At the outset patients were excluded where
we did not feel there was sufficient information to in-
clude them in our data set.
Obviously a prospective study is more favourable,
but these cases are not so common in general neuro-
logical practice. However, these psychiatric problems
are frequently encountered by specialists but are often
difficult to examine at the time of the acute psychosis,
either because they often occur when the patient is in
the community or the patient is seen by psychiatrists
rather than neurologists. All of the patients in this se-
ries have been examined by the physicians involved in
reporting these cases, increasing the quality of the data
obtained.
We believe this is the largest series of patients re-
ported who have developed such symptoms following
the onset of antiepileptic drugs, and there is some jus-
tification for including patients from three different se-
ries. However, we have shown some subtle differences
between the drugs which bear further discussion.
With regards to the overall group, we have uncov-
ered some differences between seizure patterns in pa-
tients who develop affective as opposed to psychotic
disorders. The psychotic group appear to have more
secondarily generalized seizures, and more bilateral
EEG abnormalities. This is in keeping with the sug-
gestion that psychotic states in epilepsy may be as-
sociated with more widespread cerebral abnormalities
and a propensity of seizures to spread through limbic
structures. Further, the relative under-reporting of sec-
ondarily generalized seizures in the affective disorder
group is similar to the findings of some others who
have examined links between affective disorder and
epilepsy. Flor-Henry5, for example, in his paper on pa-
tients worked up for temporal lobectomy, reported that
affective psychoses were correlated with ‘major con-
vulsive epilepsy’ infrequently manifested.
This extended sample reveals further interesting re-
lationships between the past history of psychiatric
problems and the pattern of the development of
the emergent psychiatric syndrome. Approximately a
third of our sample had no evidence of a past psy-
chiatric history, although it is possible that there was
some under-reporting here. However, the fact that two-
thirds of patients had a clear past history emphasises
the importance of a psychiatric anamnesis before start-
ing patients on these new drugs. Further, the fact that
people with a past history of depression tend to get
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Table 2: Seizure patterns before the onset of the psychiatric problem in the vigabatrin and the topiramate group.
Seizure patterns Vigabatrin Topiramate Total
N = 50 N = 34 N = 84
Psychosis Affective Psychosis Affective
N = 28 N = 22 N = 18 N = 16
Seizure-free period, followed by 7 7 5 1 20
clusters of seizures (post-ictal)
Complete suppression of seizures∗ 13 0 2 5 20
Less seizures 3 8 3 7 21
Seizures unchanged∗ 0 7 5 2 14
More seizures 0 0 3 0 3
Missing 5 0 0 1 6
∗ P < 0.01 (vigabatrin group vs. topiramate group with respect to psychiatric diagnosis).
Table 3: Diagnosis and seizure patterns before onset of the psychiatric problem in the whole sample.
Seizure patterns Psychosis Affective disorder Total
N = 49 N = 40 N = 89
Seizure-free period followed by 12 8 20
cluster of seizures (post-ictal)
Total suppression of seizures 15 7 22
Either complete suppression or 27 15 42
free period and seizure cluster∗
Seizure-free or less seizures 22 22 44
More seizures or seizures 10 9 19
unchanged
Missing 5 1 6
∗ P < 0.06.
an affective picture, and those who have a past history
of psychosis develop psychotic syndromes’ raises in-
teresting questions as to the effect of the drugs on the
central nervous system and how that leads to the emer-
gent psychiatric picture. The drugs essentially appear
to be driving the underlying constitutional liability of
these patients, the direction in which they are driven
being given by the past psychiatric profile.
Although not significant it may be relevant that
psychiatric problems were seen more commonly fol-
lowing a right hemisphere abnormality, since other
data suggest that when affective disorder or psychosis
emerge, not in a treatment setting but interictally, there
is a bias towards left hemisphere involvement6. These
data seem to fit with some recent studies7 of the re-
sults of temporal lobe surgery, where again more se-
vere psychiatric problems appear to emerge following
right hemisphere resection. These data suggest that pa-
tients with complex partial seizures that secondarily
generalize who have right hemisphere lesions may be
the more susceptible to develop psychosis if they be-
come seizure-free with these treatments.
Most patients were on polytherapy, and the vari-
ety of drugs, as expected, was wide. Interactions be-
tween different drugs, leading to the emergent psy-
chiatric syndrome cannot be speculated on, but it is
possible that these psychiatric syndromes do not oc-
cur with the same frequency when patients are treated
with monotherapy. This certainly seems to be the case
with the monotherapy trials so far published in which
psychiatric problems are less frequently reported.
We have uncovered some interesting differences be-
tween the group on vigabatrin and those on topiramate.
It is possible that these relate to selection factors. How-
ever, the vigabatrin group appeared more likely to have
an early onset of epilepsy, and an abnormal neurolog-
ical examination. This may reflect that they had more
severe epilepsy, although unexplained is the fact that
more of them also reported as having a cryptogenic
aetiology. The latter may well be an artefact of the dif-
ficulty of collecting these kind of data.
Proportionately more of the topiramate group were
receiving higher doses of the drug than for the other
drugs. When compared with vigabatrin, there was a
suggestion of more patients on topiramate with no
change, or an increase, in seizures. These data suggest
that some emergent psychiatric problems with topira-
mate may be more common following escalation of
dose. This may be due to patients being unresponsive
to the drug, and the dose therefore being increased
leading to an intoxication with topiramate. This is fur-
ther supported by the observation that patients taking
a ‘high dose’ of drugs had a longer time interval to the
onset of psychiatric problems.
We have looked at patterns of psychopathology that
emerge with alteration of seizures. It appears to be the
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case that freedom from seizures, as opposed to merely
reducing seizure frequency, is most relevant for the
development of psychosis supporting the original ob-
servations of Landolt2 and Tellenbach3. Interestingly,
there may well be a difference between topiramate and
vigabatrin again, the topiramate group having more af-
fective disorder with complete suppression of seizures.
Whether this reflects subtle biochemical differences
between the drugs is unclear. These data tend to sug-
gest that the Landolt phenomenon, which is known
from other studies8 to be associated with a variety of
clinical presentations, is more likely to be interlinked
with a productive psychosis than an affective disorder,
but that the final expression of that may be dependent
on the predisposition of the patient (see above) and the
actual drug prescribed.
In conclusion, we have studied the emergence of
psychopathology in patients who have been started on
a new antiepileptic drug. Both affective disorders and
psychoses are seen, the latter seem more interlinked
with complete suppression of seizures. There may be
subtle differences between vigabatrin and topiramate
in their biochemical effects which lead to differing
clinical profiles, which we have explored here.
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